CAMBRIDGE, Mass., June 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq:BPMC), today announced that, effective June 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 7,593 shares of its common stock and an aggregate of 3,796 restricted stock units (RSUs) to six new employees under Blueprint Medicines' 2020 Inducement Plan.
Read more at prnewswire.comBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Intel%20Corp_%20logo%20on%20mobile%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
